Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors

Miranda Toledano, Chief Executive Officer of Entera

“I am delighted to welcome Juan Camilo to Entera’s board. Juan Camilo is a distinguished clinical leader with a valuable track record in late-stage development and regulatory approvals. This, coupled with his particular focus on advancing treatments in women-centric conditions, resonates profoundly with our thesis for EB613 in late-stage development for osteoporosis and EB612 set to enter early clinical development in hypoparathyroidism. On behalf of the Board and our entire team, I would also like to extend my sincere gratitude to Haya Taitel for her commitment and contributions to Entera.”

Juan Camilo Arjona Ferreira, Head of Research and Development and Chief Medical Officer at Organon & Co.; incoming Entera board member

“EB613 represents a paradigm-shifting oral bone-forming treatment that has the potential to significantly expand appropriate care and access for millions of patients with osteoporosis – the majority of which are women after menopause who are at risk.”

Juan Camilo Arjona Ferreira, Head of Research and Development and Chief Medical Officer at Organon & Co.; incoming Entera board member

“In addition, Entera has established a unique oral peptide platform which in and of itself is likely to be valuable across multiple major disease areas. I am excited to join Miranda and her team at this pivotal stage and look forward to supporting Entera’s clinical strategy and regulatory execution.”